Cleveland BioLabs Doses First Healthy Volunteer In Initial Safety Study For Protectan CBLB502

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed under the FDA’s animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident.

More: continued here

Filed under: Bio-terrorism on October 27th, 2008